Our results provide further evidence that the combination of β2-adrenoceptor agents and anti-cholinergic agents are a promising advancement in bronchodilator therapy for COPD and asthma, and that PKC and KCa channels may be novel targets for bronchodilator research and development. The gene discussed is PRRT2; the disease is asthma.